Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 30;11(8):965–980. doi: 10.1002/1878-0261.12064

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Suppression of MAPK signaling by belinostat is associated with downregulation of SOS and leads to synergistic cytotoxicity in cisplatin‐resistant cells. (A) Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (PXD101) (0.1, 0.2, 0.3, 1, 3 μm) to evaluate the changes in SOS1 and SOS2. The combinatory effects of belinostat (1 μm) and cisplatin (10 μm) on (B) PARP, caspase 3, MEK, and ERK; and (D) SOS1 and SOS2 were examined with immunoblotting, (C) while the effects on apoptosis were evaluated with Annexin‐V/propidium iodide (PI). β‐Actin shown as loading control. Data were shown as mean ± SD. *P < 0.05.